COPENHAGEN (Reuters) - Danish pharmaceutical company Novo Nordisk said on Tuesday it has decided to stop its activities within inflammatory disorders and only focus on the treatment and prevention of diabetes and obesity. The decision follows a discontinuation for the company’s most advanced…
Source: Novo Nordisk drops inflammatory disorder business, incurs cost
Tuesday, September 2, 2014
Novo Nordisk drops inflammatory disorder business, incurs cost
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment